Q1 Earnings Forecast for NeuroPace Issued By Leerink Partnrs

NeuroPace, Inc. (NASDAQ:NPCE) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for NeuroPace in a note issued to investors on Thursday, April 3rd. Leerink Partnrs analyst M. Kratky anticipates that the company will post earnings per share of ($0.24) for the quarter. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.51) EPS, FY2027 earnings at ($0.26) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at $0.59 EPS.

A number of other brokerages have also issued reports on NPCE. JPMorgan Chase & Co. raised their price target on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Cantor Fitzgerald raised their target price on NeuroPace from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. UBS Group initiated coverage on NeuroPace in a research report on Tuesday, January 21st. They set a “buy” rating and a $17.00 price target for the company. Finally, Wells Fargo & Company lifted their price objective on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, NeuroPace presently has an average rating of “Moderate Buy” and a consensus price target of $15.20.

NeuroPace Stock Up 0.6 %

Shares of NeuroPace stock opened at $12.30 on Monday. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. NeuroPace has a 52-week low of $5.45 and a 52-week high of $15.77. The company’s 50 day moving average price is $12.52 and its 200-day moving average price is $10.49. The stock has a market capitalization of $400.49 million, a price-to-earnings ratio of -12.30 and a beta of 2.03.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.07. The business had revenue of $21.47 million for the quarter, compared to analyst estimates of $21.14 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%.

Institutional Trading of NeuroPace

Hedge funds have recently modified their holdings of the business. KCK LTD. bought a new position in shares of NeuroPace in the 4th quarter worth about $58,981,000. Jane Street Group LLC purchased a new stake in NeuroPace in the fourth quarter worth about $1,120,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of NeuroPace during the fourth quarter valued at approximately $639,000. JPMorgan Chase & Co. lifted its holdings in shares of NeuroPace by 440.4% during the fourth quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company’s stock valued at $725,000 after purchasing an additional 52,829 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of NeuroPace in the 4th quarter worth approximately $369,000. Institutional investors own 78.83% of the company’s stock.

Insider Activity at NeuroPace

In other news, major shareholder Ltd. Kck sold 5,270,845 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Martha Morrell sold 3,200 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $15.01, for a total value of $48,032.00. Following the completion of the sale, the insider now directly owns 87,062 shares in the company, valued at approximately $1,306,800.62. The trade was a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,352,479 shares of company stock worth $50,670,217 over the last 90 days. 22.20% of the stock is owned by company insiders.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.